Chabon and colleagues observed resistance mechanisms in 46% of 43 NSCLC patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.